London SPAC Ashington Agrees to $171.5M Deal with Biotech Firm | SPAC Feed

london-listed Ashington Innovation has agreed to a reverse takeover with a biotech firm less than two months after floating with the intention of attracting a fintech deal, Proactive reports.

Under the non-binding terms, Ashington will acquire 100% of the total issued equity of Cell Therapy for £135 million (US$171.5) in an all-share transaction, and will also seek a £3 million fundraise to finance the drug development program and working capital.

Cell Therapy is a clinical-stage biotechnology firm with a portfolio of patented cellular medicines with a lead program that successfully completed an early-stage human clinical trial in heart failure. Read more.

Source: London SPAC Ashington Agrees to 1.5M Deal with Biotech Firm

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
• BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
• Source: https://spacfeed.com/london-spac-ashington-agrees-to-171-5m-deal-with-biotech-firm